// App-Quantinova.ai

8019 : Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

Researchers

Presenter

  • Thierry Facon

Principal Investigators

  • Maria Gavriatopoulou

  • Sosana Delimpasi

  • Maryana Simonova

  • Ivan Spicka

  • Ludek Pour

  • Meletios A. Dimopoulos

  • Iryna Kriachok

  • Halyna Pylypenko

  • Xavier Leleu

  • HANG QUACH

  • Benjamin Reuben

  • Tuphan Kanti Dolai

  • Dinesh Kumar Sinha

  • Mamta Garg

  • Don A. Stevens

  • Jatin J. Shah

  • Paul G. Richardson

  • Sebastian Grosicki

Medical Centers

  • University of Lille, CHU Lille, Service des Maladies du Sang,Lille,Frankreich

  • School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

  • General Hospital Evangelismos, Athens, Greece

  • Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine, Lviv, Ukraine

  • Lviv, Ukraine

  • 1st Internal Clinic–Clinic of Hematology, General University Hospital, Prague, Czech Republic, Fakultní nemocnice Brno, Brno, Czech Republic, Therapeutic Clinic, General Hospital of Athens Alexandra, Athens, Greece

  • Institute of Oncology AMS Ukraine

  • Kiev, Ukraine

  • 'Cherkasy Regional Oncology Dispensary' of Cherkasy Regional Council, Regional Treatment and Diagnostic Hematology Center,Cherkasy,Ukraine

  • Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France

  • St Vincents Hospital University of Melbourne, Fitzroy, VIC, Australia

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Nil Ratan Sircar Medical College and Hospital, Kolkata, India

  • State Cancer Institute, Indira Gandhi Institute of Medical Sciences,Patna,India

  • Department of Haematology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

  • Louisville Onc, Louisville, KY, Karyopharm Therapeutics Inc., Newton, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Department of Hematology, Independent Public Healthcare Facility Municipal Hospitals, Katowice, Poland

Locations

  • France

  • United Kingdom

  • Greece

  • Ukraine

  • Australia

  • India

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

  • Selinexor

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03110562

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved